Statistical analysis plan (SAP)
A statistical analysis plan is where trial design decisions become regulator-ready evidence. At KLIFO, we develop SAPs that lock in scientific intent early, withstand regulatory scrutiny, and integrate seamlessly with protocol execution and clinical reporting.
Our role is not theoretical. We take responsibility for SAP development as a governing document that supports clinical operations, regulatory alignment, and downstream CSR delivery.
When a statistical analysis plan becomes critical
Sponsors typically require a formal SAP when development moves from exploratory intent to generation of decision-making data. This often coincides with key inflection points in the overall development program.
Common triggers include pivotal or registration-enabling studies, expansion cohorts intended to support regulatory submissions, complex oncology designs with stopping rules, and trials where interim analyses or adaptive elements influence decision pathways. SAPs are also required when regulators expect prospective agreement on analysis assumptions before data unblinding or database lock.
In these situations, the SAP becomes a regulatory commitment rather than an internal working document..
What KLIFO delivers
KLIFO delivers a complete, regulator-ready statistical analysis plan that supplements the clinical trial protocol and governs how trial data will be analyzed, interpreted, and presented.
The SAP is developed alongside protocol finalization and aligned with operational realities, data availability, and reporting requirements. It pre-specifies all assumptions, analysis populations, methods, and decision rules that could otherwise introduce bias or post-hoc interpretation risk.
Clients receive a standalone SAP document suitable for inclusion in regulatory submissions and CSR appendices, written with sufficient precision to support both execution and review.
SAP templates vs. trial-specific SAPs
Templates can be useful as structural starting points, especially early in development. But they are not substitutes for a trial-specific statistical analysis plan. In practice, regulatory risk rarely comes from missing headings. It comes from assumptions, decision rules, and analytical choices that are not fully aligned with the protocol, the study objectives, the data or how the trial will actually be executed.
At KLIFO, SAPs are developed as trial-specific governing documents. The statistical approach is shaped around the design, endpoints, interim decision logic, and regulatory intent of the individual study, rather than fitted into a generic framework. This ensures that estimands, analysis populations, stopping rules, and sensitivity analyses are internally consistent and defensible once data are locked and results are reviewed.
Integration with trial execution and reporting
A SAP only reduces risk if it reflects how the trial will actually be conducted. KLIFO develops the SAP in close coordination with protocol authors, data management, programming teams, and clinical operations.
This alignment ensures that assumptions made in the SAP are operationally feasible, that interim analyses can be executed without governance gaps, and that outputs map directly to CSR requirements. The result is a document that supports both trial conduct and regulatory review, rather than creating friction between functions.
Where relevant, SAP development is coordinated with Clinical Operations to ensure consistency between analytical assumptions, visit schedules, and data capture.s.
Regulatory alignment and expectations
SAPs are expected to be finalised before key milestones such as database lock, unblinding, or regulatory interaction for pivotal studies. Regulators increasingly assess not only whether a SAP exists, but whether the content was prospectively defined, internally consistent, and suitable for the study objectives.
KLIFO develops SAPs in alignment with internationally accepted statistical and quality frameworks, including ICH E9 and ICH E3, ensuring that methodological choices are defensible and clearly documented.
This reduces the risk of late-stage questions, re-analysis requests, or challenges to interpretability during review.
What typically goes wrong with SAPs
In practice, SAP-related issues often arise not from missing sections, but from poor integration and late decisions.
Common failure points include unclear estimands that do not match protocol endpoints, stopping rules that are not operationally executable, insufficient planning for missing data, and SAPs finalized too close to unblinding to be considered genuinely prospective.
These issues can undermine confidence in trial results, delay regulatory interactions, and complicate CSR preparation. KLIFO’s approach is designed to prevent these risks by treating the SAP as a strategic document, not a formality.
Why sponsors involve KLIFO
Sponsors work with KLIFO when SAP development needs to be low-risk, efficient, and defensible.
Our teams combine statistical seniority with deep understanding of drug development, regulatory expectations, and operational execution. We do not deliver generic templates or academic exercises. We deliver SAPs that stand up in real programs, under real regulatory scrutiny.
KLIFO is typically engaged when internal resources are stretched, when prior SAPs have raised concerns, or when programs cannot afford avoidable regulatory questions later in development.
SAPs as part of an end-to-end delivery
Statistical analysis plans rarely exist in isolation. They sit between protocol development, trial execution, and clinical study reporting.
KLIFO develops SAPs with full awareness of their downstream role in the Clinical Study Report, where statistical methodology is formally documented and reviewed. This continuity reduces rework, supports consistent interpretation, and strengthens the credibility of submitted data.
For sponsors seeking a partner who can take responsibility across this chain, SAP development becomes a natural extension of KLIFO’s end-to-end delivery model.